Skip to main content
SpringerLink
Log in

Pharmacological Agents and Portal Hypertension

  • Chapter
Portal Hypertension

Abstract

The pharmacological treatment of portal hypertension includes both the treatment of the acute bleeding episode and prevention of variceal bleeding [1]. The latter may be subdivided in two different clinical situations: prevention of variceal rebleeding in patients who have already bled from their varices and prophylaxis of the first hemorrhage.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bosch J, Navasa M, García-Pagán JC, DeLacy AM, Rodés J (1989) Portal hypertension. Med Clin N Am 73: 931–953

    PubMed  CAS  Google Scholar 

  2. Bosch J (1984) ¿Por qué sangran las varices esofágicas?. Med Clin (Barc) 82: 401–403

    CAS  Google Scholar 

  3. Polio J, Groszmann RJ (1986) Hemodynamic factors involved in the development and rupture of esophageal varices: A pathophysiologic approach to treatment. Semin Liver Dis 6: 318–331

    Article  PubMed  CAS  Google Scholar 

  4. Bosch J, Groszmann RJ (1984) Measurement of the azygos venous blood flow by a continuous thermodilution technique. An index of blood flow through gastroesophageal collaterals in cirrhosis. Hepatology 4: 424–429

    Article  PubMed  CAS  Google Scholar 

  5. Bosch J (1985) Effect of pharmacological agents on portal hypertension: A haemodynamic appraisal. Clin Gastroenterol 1: 169–184

    Google Scholar 

  6. Bosch J, Mastai R, Kravetz D, Navasa M, Rodés J (1986) Hemodynamic evaluation of the patient with portal hypertension. Semin Liver Dis 4: 309–317

    Article  Google Scholar 

  7. Lebrec D (1987) Drugs for portal hypertension. J Gastroenterol Hepatol 2: 361–374

    Article  Google Scholar 

  8. Barbare JC, Poupon R, Jaillon P, Bories P, Aussanaire M, Darnis F, Michel H, Cheymol G (1984) The influence of vasoactive agents on metabolic activity of the liver in cirrhosis: A study of the effects of posterior pituitary extract, vasopressin, and somatostatin. Hepatology 4: 59–62

    Article  PubMed  CAS  Google Scholar 

  9. Bosch J, Kravetz D, Rodés J (1981) Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver. Comparison with vasopressin. Gastroenterology 80: 518–525

    PubMed  CAS  Google Scholar 

  10. Groszmann RJ, Kravetz D, Bosch J, Glickmann M, Bruix J, Bredfeldt J, Conn HO, Rodés J, Storer EH (1982) Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Hepatology 2: 757–762

    Article  PubMed  CAS  Google Scholar 

  11. Bosch J, Kravetz D, Navasa M (1987) Effects of vasopressin on variceal pressure and azygos blood flow. In: Lebrec D, Blei AT (eds) Vasopressin analogs and portal hypertension. John Libbey Eurotext, Paris, pp 95–104

    Google Scholar 

  12. Bosch J, Bordas JM, Mastai R, Kravetz D, Navasa M, Chesta J, Pizcueta MP, Carcía-Pagán JC, Rodés J (1988) Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: Comparison with the effects on portal pressure. Hepatology 8: 861–865

    Article  PubMed  CAS  Google Scholar 

  13. Poupon R, Islam S, Chretien Y, Ballet F (1987) Effects of vasopressin on hepatic metabolic activity in cirrhosis. In: Lebrec D, Blei AT (eds) Vasopressin analogs and portal hypertension. John Libbey Eurotext, Paris, pp 75–82

    Google Scholar 

  14. Bichet D, Schrier RW (1987) Endogenous vasopressin in liver disease. In: Lebrec D, Blei AT (eds) Vasopressin analogs and portal hypertension. John Libbey Eurotext, Paris, pp 37–47

    Google Scholar 

  15. Zito RA, Diez AR, Groszmann RJ (1983) Comparative effect of nitroglycerin and nitroprusside on vasopressin-induced cardiac dysfunction in the dog. J Cardiovasc Pharmacol 5: 586–591

    Article  PubMed  CAS  Google Scholar 

  16. Bosch J, Grosmann RJ, García-Pagán JC, Terés J, García-Tsao G, Navasa M, Mas A, Rodés J (1989) Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo-controlled clinical trial. Hepatology 10: 962–968

    Article  PubMed  CAS  Google Scholar 

  17. Kravetz D, Bosch J, Terés J, Bruix J, Rimola A, Rodés J (1984) Comparison of intravenous somatostatin and vasopressin infusions in treatment of acute variceal hemorrhage. Hepatology 4: 442–446

    Article  PubMed  CAS  Google Scholar 

  18. Barr JW, Robert CL, Rösch J (1975) Similarity of arterial and intravenous vasopressin on portal and systemic hemodynamics. Gastroenterology 69: 13–19

    PubMed  CAS  Google Scholar 

  19. Millet B, Huet PM, Lavoie P, Viallet A (1975) Portal and systemic effects of selective infusion of vasopressin into the superior mesenteric artery in cirrhotic patients. Gastroenterology 69: 6–12

    Google Scholar 

  20. Huet PM, Valla D, Lafortune M, Marleau D (1987) Hemodynamic effects of vasopressin in cirrhotic patients. In: Lebrec D, Blei AT (eds) Vasopressin analogs and portal hypertension. John Libbey Eurotext, Paris, pp 83–94

    Google Scholar 

  21. Groszmann RJ (1987) Vasopressin and nitroglycerin In: Lebrec D, Blei AT (eds) Vasopressin analogues and portal hypertension. John Libbey Eurotext, Paris, pp 113–123

    Google Scholar 

  22. Westaby D, Gimson A, Hayes PC, Williams R (1988) Haemodynamic response to intravenous vasopressin and nitroglycerin in portal hypertension. Gut 29: 372–377

    Article  PubMed  CAS  Google Scholar 

  23. Kravetz D, Cummings SA, Groszmann RJ (1987) Hyposensitivity to vasopressin in a hemorrhaged-transfused rat model of portal hypertension. Gastroenterology 93: 170–175

    PubMed  CAS  Google Scholar 

  24. Valla D, Geoffroy P, Girod C, Lebrec D (1986) Circulatory actions of vasopressin in anaesthetized rats with portal hypertension subjected to haemorrhage. J Hepatol 2: 328–339

    Article  PubMed  CAS  Google Scholar 

  25. Valla D, Girod C, Lee SS, Braillon A, Lebrec D (1988) Lack of vasopressin action on splanchnic hemodynamics during bleeding: A study in conscious, portal hypertensive rats. Hepatology 8: 10–15

    Article  PubMed  CAS  Google Scholar 

  26. Blei AT, Groszmann RJ, Gusberg R, Conn HO (1980) Comparison of vasopressin and triglycyllysine vasopressin on splanchnic and systemic hemodynamics in dogs. Dig Dis Sci 25: 688–694

    Article  PubMed  CAS  Google Scholar 

  27. Merkerl C, Gatta A, Bolognesi M, Finucci G, Battaglia G, Angeli P, Zuin R (1988) Hemodynamic changes of systemic, hepatic, and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis. Dig Dis Sci 33: 1103–1109

    Article  Google Scholar 

  28. Valla D, Lee SS, Moreau R, Hadengue A, Sayegh R, Lebrec D (1985) Efects de la glypressine sur les circulations splanchnique et systémique des malades atteints de cirrhose. Gastroenterol Clin Biol 9: 877–880

    PubMed  CAS  Google Scholar 

  29. Tyden G, Samnegard H, Thulin L, Friman L, Efendic S (1978) Treatment of bleeding esophageal varices with somatostatin. (correspondence) N Engl J Med 299: 1466–1467

    Article  PubMed  CAS  Google Scholar 

  30. Bosch J, Kravetz D, Mastai R, Navasa M, Silva G, Chesta J, Rodés J (1988) Effects of somatostatin in patients with portal hypertension. Horm Res 29: 99–102

    Article  PubMed  CAS  Google Scholar 

  31. Eriksson LS, Law DH, Sato Y, Wahren J (1984) Influences of somatostatin on splanchnic haemodynamics in patients with liver cirrhosis. Clin Physiol 4: 5–11

    Article  PubMed  CAS  Google Scholar 

  32. Kravetz D, Bosch J, Arderiu MT, Pizcueta MP, Casamitjana R, Rivera F, Rodés J (1988) Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am J Physiol 254: G322–G328

    PubMed  CAS  Google Scholar 

  33. Clements D, Rhodes JM, Elias E (1986) Effect of somatostatin on oesophageal variceal pressure assessed by direct measurement. J Hepatol 2: 262–266

    Article  PubMed  CAS  Google Scholar 

  34. Jenkins SA, Baxter JN, Corbett WA, Shields R (1985) Effects of a somatostatin analogue SMS 201–995 on hepatic haemodynamics in the pig and on intravariceal pressure in man. Br J Surg 72: 1009–1012

    Article  PubMed  CAS  Google Scholar 

  35. Kleber G, Sauerbruch T, Fischer G, Paumgartner G (1988) Somatostatin does not reduce oesophageal variceal pressure in liver cirrhosis. Gut 29: 153–156

    Article  PubMed  CAS  Google Scholar 

  36. Eriksson LS, Brundin T, Söderlund C, Wahren J (1987) Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis. Scand J Gastroenterol 22: 919–925

    Article  PubMed  CAS  Google Scholar 

  37. Cerini R, Lee SS, Hadengue A, Koshy A, Girod C, Lebrec D (1988) Circulatory effects of somatostatin analogue in two conscious rat models of portal hypertension. Gastroenterology 94: 703–708

    PubMed  CAS  Google Scholar 

  38. Navasa M, Bosch J, Chesta J, Bru C, Pizcueta P, García-Pagán JC, Betz C, Casamitjana R, Rodés J (1988) Haemodynamic effects of subcutaneous administration of SMS 201–995, a long acting somatostatin analog, in patients with cirrhosis and portal hypertension (abstract). J Hepatol 7: s64

    Google Scholar 

  39. Burroughs AK, Jenkins WJ, Sherlock S, Dunk A, Walt RP, Osuafor TOK, Mackie S, Dick R (1983) Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med 309: 1539–1542

    Article  PubMed  CAS  Google Scholar 

  40. Calès P, Pascal JP, and a multicenter study group (1987) Propranolol in the prevention of the first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 317: 856–861

    Article  PubMed  Google Scholar 

  41. Colombo M, De Franchis R, Tommasini M, Sangiovanni A, Dioguardi N (1989) β-Blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: A multicenter randomized controlled trial. Hepatology 9: 433–438

    Article  PubMed  CAS  Google Scholar 

  42. Lebrec D, Poynard T, Bernuau J, Bercoff E, Nouel O, Capron JP, Poupon R, Bouvry M, Rueff B, Benhamou JP (1984) A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: A final report. Hepatology 4: 355–358

    Article  PubMed  CAS  Google Scholar 

  43. Villeneuve JP, Pomier-Layrargues G, Infante-Rivard C, Willems B, Huet PM, Marleau D, Viallet A (1986) Propranolol for the prevention of recurrent variceal hemorrhage: A controlled trial. Hepatology 6: 1239–1243

    Article  PubMed  CAS  Google Scholar 

  44. Abshagen U, Betzien G, Endele R, Kaufmann B (1981) Pharmacokinetics of intravenous and oral isosorbide 5 mononitrade. Eur J Pharmacol 20: 269–275

    Article  CAS  Google Scholar 

  45. Bhathal PS, Grossmann HJ (1985) Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1: 325–337

    Article  PubMed  CAS  Google Scholar 

  46. Lebrec D, Hillon P, Muñoz C, Goldfarb G, Nouel O, Benhamou JP (1982) The effect of propranolol on portal hypertension in patients with cirrhosis: A hemodynamic study. Hepatology 2: 523–527

    Article  PubMed  CAS  Google Scholar 

  47. Bosch J, Mastai R, Kravetz D, Bruix J, Gaya J, Rigau J, Rodés J (1984) Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 4: 1200–1205

    Article  PubMed  CAS  Google Scholar 

  48. Calès P, Braillon A, Girod C, Lebrec D (1985) Acute effects of propranolol on splanchnic circulation in normal and portal hypertensive rats. J Hepatol 1: 349–357

    Article  PubMed  Google Scholar 

  49. Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM, Patrick MJC, Morse SS, Alberts JL (1986) Short-term effects of propranolol on portal venous pressure. Hepatology 6: 101–106

    Article  PubMed  CAS  Google Scholar 

  50. García-Pagán JC, Navasa M, Ruiz del Arbol L, Gaya J, Pizcueta P, Feu F, Rivera F, Bosch J, Rodés J (1989) Lymphocyte Beta-2 adrenoceptors, plasma catecholamines and haemodynamic response to propranolol in patients with cirrhosis and portal hypertension. J Hepatol S1: S34

    Article  Google Scholar 

  51. Kroeger RJ, Groszmann RJ (1985) Increased portal venous resistance hinders portal pressure reduction during the administration of β-adrenergic blocking agents in a portal hypertension model. Hepatology 5: 97–101

    Article  PubMed  CAS  Google Scholar 

  52. Valla D, Gaudin C, Geoffroy P, Braillon A, Lee SS, Lebrec D (1987) Reversal of adrenaline-induced increase in azygos blood flow in patients with cirrhosis receiving propranolol. J Hepatol 4: 86–92

    Article  PubMed  CAS  Google Scholar 

  53. Mastai R, Bosch J, Navasa M, Kravetz D, Bruix J, Viola C, Rodés J (1987) Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flowand splanchnic haemodynamics in patients with cirrhosis. J Hepatol 4: 71–79

    Article  PubMed  CAS  Google Scholar 

  54. Koshy A, Girod C, Lee SS, Hadengue A, Cerini R, Lebrec D (1989) Discrepancy between portal pressure and systemic hemodynamic changes after incremental doses of propranolol in awake portal hypertensive rats. Hepatology 9: 269–273

    Article  PubMed  CAS  Google Scholar 

  55. Vorobioff J, Picabea E, Villavicencio R, Puccini V, Rossi O, Bordato J, Audano M (1987) Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patiens. Hepatology 7: 648–653

    Article  PubMed  CAS  Google Scholar 

  56. Groszmann RJ, Bosch J, Grace N, Conn HO, García-Tsao G, Navasa M, Albert J, Bermann M, Patrick M, Rodés J (1988) Hemodynamic events in a prospective randomized trial of propranolol vs placebo in the prevention of the first variceal hemorrhage. Hepatology 5: 1242

    Google Scholar 

  57. Mastai R, Bosch J, Bruix J, Navasa N, Kravetz D, Rodés J (1989) β-Blockade with propranolol and hepatic artery blood flow in patients with cirrhosis. Hepatology 10: 269–272

    Article  PubMed  CAS  Google Scholar 

  58. Vinel JP, Caucanas JP, Cales P, Suduca JM, Voigt JJ, Pascal JP (1988) Effect of propranolol on metabolic activity of the liver in patients with alcoholic cirrhosis. J Hepatol 7: 186–192

    Article  PubMed  CAS  Google Scholar 

  59. Lebrec D (1989) Propranolol and portal hypertension. In: Bosch J, Rodés J (eds) Recent advances in the pathophysiology and therapy of portal hypertension. Ares-Serono Symposia, Rome, pp 219–235

    Google Scholar 

  60. Merkel C, Sacerdoti D, Finucci GF, Zuin R, Bazzerla G, Bolognesi M, Gatta A (1986) Effect of nadolol on liver haemodynamics and function in patients with cirrhosis. Br J Clin Pharmacol 21: 713–719

    Article  PubMed  CAS  Google Scholar 

  61. Hillon P, Lebrec D, Muñoz C, Jungers M, Goldfarb G, Benhamou JP (1982) Comparison of the effects of a cardioselective and a nonselective β-blocker on portal hypertension in patients with cirrhosis. Hepatology 2: 528–531

    Article  PubMed  CAS  Google Scholar 

  62. Mills PR, Rae AP, Farah DA, Russell RI, Lorimer AR, Carter DC (1984) Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension. Gut 25: 73–78

    Article  PubMed  CAS  Google Scholar 

  63. Ideo G, Bellati G, Fesce E, Grimoldi D (1988) Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: A prospective, randomized study. Hepatology 8: 6–9

    Article  PubMed  CAS  Google Scholar 

  64. Blei AT (1989) Vasodilator therapy of portal hypertension: Focus on the liver. Hepatology 9: 896–899

    Article  PubMed  CAS  Google Scholar 

  65. Reichen J, Le M (1986) Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver. J Clin Invest 78: 448–455

    Article  PubMed  CAS  Google Scholar 

  66. Blei At, García-Tsao G, Groszmann RJ, Kahrilas P, Ganger D, Morse S, Fung HL (1987) Hemodynamic evaluation of isosorbide dinitrate in alcoholic cirrhosis. Pharmacokinetic-hemodynamic interactions. Gastroenterology 93: 576–583

    PubMed  CAS  Google Scholar 

  67. Blei AT, Gottstein J (1986) Isosorbide dinitrate in experimental portal hypertension: a study of factors that modulate the hemodynamic response. Hepatology 6: 107–111

    Article  PubMed  CAS  Google Scholar 

  68. Garcia-Tsao G, Groszmann RJ (1987) Portal hemodynamics during nitroglycerin administration in cirrhotic patients. Hepatology 7: 805–809

    Article  PubMed  CAS  Google Scholar 

  69. Navasa M, Bosch J, Chesta J, Rodés J (1989) Isosorbide-5-mononitrate reduces hepatic vascular resistance and portal pressure in patients with cirrhosis. Gastroenterology 96: 1110–1118

    PubMed  CAS  Google Scholar 

  70. Freeman G, Barton JR, Record CO (1985) Effect of isosorbide dinitrate, verapamil and labetalol in portal pressure in cirrhosis. Br Med J 291: 561–562

    Article  CAS  Google Scholar 

  71. Merkel C, Finucci G, Zuin R, Bazzerla G, Bolognesi M, Sacerdoti D, Gatta A (1987) Effects of isosorbide dinitrate in alcoholic cirrhosis. J Hepatol 4: 174–180

    Article  PubMed  CAS  Google Scholar 

  72. Dawson J, Gertsch P, Mosimann F, West R, Elias E (1985) Endoscopic variceal pressure measurements: response to isosorbide dinitrate. Gut 26: 843–847

    Article  PubMed  CAS  Google Scholar 

  73. Henriksen JH, Ring-Larsen H, Christensen NJ (1984) Sympathetic nervous activity in cirrhosis. A survey of plasma catecholamine studies. J Hepatol 1: 55–65

    Article  CAS  Google Scholar 

  74. Mols P, Hallemans R, Melot C, Lejeune P, Naeije R (1989) Systemic and regional hemodynamic effects of isosorbide dinitrate in patients with liver cirrhosis and portal hypertension. J Hepatol 1989 8: 316–324

    Article  PubMed  CAS  Google Scholar 

  75. García-Pagán JC, Feu F, Navasa M, Bru C, Ruiz del Arbol L, Bosch J, Rodés J (1990) Long-term hemodynamic effects of isosorbide-5-mononitrate in patients with cirrhosis and portal hypertension. J Hepatol 11: 189–195

    Article  PubMed  Google Scholar 

  76. Vinel JP, Monnin JL, Combis JM, Calés P, Desmorat H, Pascal JP (1990) Hemodynamic evaluation of molsidomine: A vasodilator with antianginal properties in patients with alcoholic cirrhosis. Hepatology 11: 239–242

    Article  PubMed  CAS  Google Scholar 

  77. Vinel JP, Caucanas JP, Combis JM, Claes P, Voigt JJ, Pascal JP (1989) Verapamil has no effect on porto-hepatic pressure gradient, hepatic blood flow and elimination function of the liver in patients with cirrhosis. J Hepatol 8: 302–307

    Article  PubMed  CAS  Google Scholar 

  78. Navasa M, Bosch J, Reichen J, Bru C, Mastai R, Zysset T, Silva G, Rodés J (1988) Effects of verapamil on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension. Hepatology 8: 850–854

    Article  PubMed  CAS  Google Scholar 

  79. Marteau P, Ballet F, Chazouillères, Chrétien Y, Rey C, Petit D, Poupon R (1989) Effect of vasodilators on hepatic microcirculation in cirrhosis: A study in the isolated perfused rat liver. Hepatology 9: 820–823

    Article  PubMed  CAS  Google Scholar 

  80. Koshy A, Hadengue A, Lee SS, Jirón MI, Lebrec D (1987) Possible deleterious hemodynamic effect of nifedipine on portal hypertension in patients with cirrhosis. Clin Pharmacol Ther 42: 295–298

    Article  PubMed  CAS  Google Scholar 

  81. Cummings SA, Groszmann RJ, Kaumann AJ (1986) Hypersensitivity of mesenteric veins to 5-hydroxytryptamine and ketanserin-induced reduction of portal pressure in portal hypertensive rats. Br J Pharmacol 89: 501–513

    Article  PubMed  CAS  Google Scholar 

  82. Kaumann AJ, Morgan JS, Groszmann RJ (1988) ICI169, 369 selectively blocks 5-hydroxytryptamine-2 receptors and lowers portal pressure in portal hypertensive rats. Gastroenterology 95: 1601–1606

    PubMed  CAS  Google Scholar 

  83. Hadengue A, Lee SS, Moreau R, Braillon A, Lebrec D (1987) Beneficial hemodynamic effects of ketanserin in patients with cirrhosis: Possible role of serotoninergic mechanisms in portal hypertension. Hepatology 7: 644–647

    Article  PubMed  CAS  Google Scholar 

  84. Vorobioff J, Garcia-Tsao G, Groszmann RJ, Aceves G, Picabea E, Villavicencio R, Hernandez-Ortiz J (1989) Long-term hemodynamic effects of ketanserin, a 5-hydroxytryptamine blocker, in portal hypertensive patients. Hepatology 9: 88–91

    Article  PubMed  CAS  Google Scholar 

  85. Cummings SA, Kaumann AJ, Groszmann RJ (1988) Comparison of the hemodynamic responses to ketanserin and prazosin in portal hypertensive rats. Hepatology 8: 1112–1115

    Article  PubMed  CAS  Google Scholar 

  86. Mastai R, Rocheleau B, Huet PM (1989) Serotonin blockade in conscious, unrestrained cirrhotic dogs with portal hypertension. Hepatology 9: 265–268

    Article  PubMed  CAS  Google Scholar 

  87. Pariente A, Bataille C, Bercoff E, Lebrec D (1985) Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology 88: 1255–1259

    PubMed  CAS  Google Scholar 

  88. Eriksson LS, Kagedal B, Wahren J (1984) Effects of captopril on hepatic venous pressure and blood flow in man. Am J Med 76: 66–70

    Article  PubMed  CAS  Google Scholar 

  89. Moreau R, Lee SS, Hadengue A, Braillon A, Lebrec D (1987) Hemodynamic effects of a clonidine-induced decrease in sympathetic tone in patients with cirrhosis. Hepatology 7: 149–154

    Article  PubMed  CAS  Google Scholar 

  90. Willet IR, Jennings G, Esther M, Dudley FJ (1896) Sympathetic tone modulates portal venous pressure in cirrhosis. Lancet II: 939–942

    Google Scholar 

  91. Kroeger RJ, Groszmann RJ (1985) The effect of the combination of nitroglycerin and propranolol on splanchnic and systemic hemodynamics in a portal hypertensive rat model. Hepatology 5: 425–430

    Article  PubMed  CAS  Google Scholar 

  92. García-Pagán JC, Navasa M, Bosch J, Bru C, Pizcueta P, Rodés J (1990) Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology 11: 230–238

    Article  PubMed  Google Scholar 

  93. Hadengue A, Moreau R, Cerini R, Koshy A, Lee S, Lebrec D (1989) Combination of ketanserin and verapamil or propranolol in patients with alcoholic cirrosis: Search for an additive effect. Hepatology 9: 83–87

    Article  PubMed  CAS  Google Scholar 

  94. Miskowik J (1978) How the lower oesophageal sphincter affects submucosal oesophageal varices. Lancet II: 1284–1285

    Article  Google Scholar 

  95. Miskowik J, Burcharth F, Jensen L (1981) Effect of lower oesophageal sphincter on oesophageal varices. A portographic study. Scand J Gastroenterol 16: 957–960

    Article  Google Scholar 

  96. Mastai R, Grande L, Bosch J, Bruix J, Rigau J, Kravetz D, Navasa M, Pera C, Rodés J (1986) Effects of metoclopramide and domperidone on azygos venous blood flow in patients with cirrhosis and portal hypertension. Hepatology 6: 1244–1247

    Article  PubMed  CAS  Google Scholar 

  97. Hosking SW, Doss W, El-Zeiny H, Robinson P, Barsoum MS, Johnson AG (1988) Pharmacological constriction of the lower oesophageal sphincter: a simple method of arresting variceal haemorrhage. Gut 29, 1098–1102

    Article  PubMed  CAS  Google Scholar 

  98. Braillon A, Capron-Chivrac D, Valla D, Lee S, Capron JP, Lebrec D (1986) Domperidone-induced increase in lower oesophageal sphincter pressure does not affect azygos blood flow in patients with cirrhosis. Scand J Gastroenterol 21: 1080–1082

    Article  PubMed  CAS  Google Scholar 

  99. Feu F, Mas A, Bosch J, Salmerón JM, García-Pagán JC, Terés J, Rodés J (1988) Domperidone or metoclopramide vs. placebo in the prevention of early variceal rebleeding in cirrhosis. A prospective randomized trial. J Hepatol S1, 7: S31

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Liver Unit, Hospital Clinic i Provincial, University of Barcelona, 08 034, Barcelona, Spain

    Joan Rodés

Authors
  1. Miquel Navasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaime Bosch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joan Rodés
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, Chiba University Hospital, Inohana 1-8-1, Chiba, 280, Japan

    Kunio Okuda M.D., Ph.D. (Professor) (Professor)

  2. Department of Hepatology, Hopital Beaujon, 92118, Clichy, France

    Jean-Pierre Benhamou M.D. (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer Japan

About this chapter

Cite this chapter

Navasa, M., Bosch, J., Rodés, J. (1991). Pharmacological Agents and Portal Hypertension. In: Okuda, K., Benhamou, JP. (eds) Portal Hypertension. Springer, Tokyo. https://doi.org/10.1007/978-4-431-68361-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-68361-2_4

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-68363-6

  • Online ISBN: 978-4-431-68361-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation